Amicus Therapeutics (FOLD)

P/S ratio as of November 2024 (TTM): 6.80

According to Amicus Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 17.3. At the end of 2024 the company had a P/S ratio of 6.45.

P/S ratio history for Amicus Therapeutics from 2009 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	6.45	-38.11%
2023	10.4	0%
2022	10.4	-1.09%
2021	10.5	-54.33%
2020	23.1	68.95%
2019	13.7	-31.34%
2018	19.9	-69.31%
2017	64.8	-54.59%
2016	143
2015	N/A	-100%
2014	650	61.89%
2013	401	5453.47%
2012	7.22	29.9%
2011	5.56	-96.84%
2010	176	12477.63%
2009	1.40

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Biogen BIIB	2.54	-62.72%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	4.62	-32.14%	🇺🇸 USA
Esperion Therapeutics ESPR	1.73	-74.60%	🇺🇸 USA
GlaxoSmithKline GSK	1.81	-73.41%	🇬🇧 UK
Lexicon Pharmaceuticals LXRX	119	1,653.47%	🇺🇸 USA
Novo Nordisk NVO	13.2	94.62%	🇩🇰 Denmark

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Amicus Therapeutics (FOLD)

P/S ratio as of November 2024 (TTM): 6.80